论文部分内容阅读
目的:观察SF方案对代偿性乙型肝炎肝硬化患者的治疗作用。方法:代偿性乙肝肝硬化患者63例,分为治疗组33例,对照组30例。治疗组采用SF方案进行治疗,对照组采用常规护肝疗法,疗程为9～12个月,定期监测肝功能指标变化。结果:SF方案对肝硬化有较好的疗效,一是肝脏炎症反应减轻,肝功能恢复,血清ALT、AST、TBiL经治疗后治疗组均显著低于治疗前和同期对照组;二是阻止肝纤维化进展,肝纤维化指标明显好转;三是免疫功能得以改善,外周血CD4/CD8淋巴细胞比值回升,补体C3水平上升;四是抗病毒效果显著,HBVDNA阴转率达54.5%。结论:SF方案有显著改善患者肝功能,恢复患者免疫功能,抑制病毒增殖的作用,可扩大样本量进一步研究。
Objective: To observe the therapeutic effects of SF regimen on patients with decompensated hepatitis B cirrhosis. Methods: 63 patients with compensated hepatitis B cirrhosis were divided into treatment group (n = 33) and control group (n = 30). The treatment group was treated with SF regimen, while the control group was treated with routine hepatoprotective therapy. The course of treatment was 9 to 12 months. The changes of liver function indexes were monitored regularly. Results: The SF regimen has a good effect on cirrhosis. The first is the reduction of liver inflammation and the restoration of liver function. The levels of serum ALT, AST and TBiL after treatment in the treatment group were significantly lower than those in the control group before treatment and in the same period. Second, Fibrosis, liver fibrosis index improved significantly; Third, immune function can be improved, peripheral blood CD4 / CD8 lymphocyte ratio rose, complement C3 levels rise; Fourth, the anti-virus effect is significant, HBVDNA negative conversion rate of 54.5%. Conclusion: The SF regimen can significantly improve the liver function, restore immune function and inhibit the proliferation of the virus, and can further expand the sample size.